Three biotech outfits just brought in fresh legal chiefs as venture capital money starts flowing back into the sector after getting wrecked for two years straight. Sudo Biosciences grabbed Paul Bavier from HilleVax to be their first-ever chief legal officer, PepGen made Joseph Vittiglio the top business and legal guy after he spent months consulting for them, and Tonix Pharmaceuticals tapped Irina Ishak from Lowenstein Sandler, where she already repped them as outside counsel since 2017.
Bavier brings decades of experience handling IPOs and acquisitions, while Sudo works on anti-inflammatory drugs for autoimmune conditions. Vittiglio previously held the same role at Bluebird Bio before jumping to PepGen, which develops treatments for neuromuscular diseases. Ishak advised Tonix on financing deals and licensing agreements before getting promoted from external counsel to full-time general counsel at the fibromyalgia drug developer.
Bavier brings decades of experience handling IPOs and acquisitions, while Sudo works on anti-inflammatory drugs for autoimmune conditions. Vittiglio previously held the same role at Bluebird Bio before jumping to PepGen, which develops treatments for neuromuscular diseases. Ishak advised Tonix on financing deals and licensing agreements before getting promoted from external counsel to full-time general counsel at the fibromyalgia drug developer.
